VistaGen Therapeutics (VTGN)

• Market cap: $10.2M
• 1 day: 1.14%
• 5 days: 6.82%
• 1 month: -56.56%
• 3 months: -59.29%
• 6 months: -62.91%
• Year to date: -63.34%
• 1 year: -88.94%
• 5 years: -99.71%
• 10 years: -99.77%
• Sector: Healthcare
• Industry: Biotechnology

About: Vistagen Therapeutics Inc is a late clinical-stage therapeutics company focused on developing and commercializing medicines for patients with social anxiety disorder, depression, menopausal hot flashes, psychomotor impairment due to mental fatigue, and cancer cachexia. The company is engaged in developing intranasal product candidates called pherines, which leverage the understanding of nose-to-brain neurocircuitry. Vistagen's pherine pipeline consists of various product candidates like: Fasedienol, Itruvone, PH15, Refisolone, and PH284, which are being developed to provide treatment for a variety of disorders. Additionally, it is seeking potential partners for the further clinical development and commercialization of an oral drug candidate, AV-101, to treat certain neurological disorders.

Employees: 41